ESCRS - Staining solution for cataract surgeries available as vial and syringe ;
ESCRS - Staining solution for cataract surgeries available as vial and syringe ;

Staining solution for cataract surgeries available as vial and syringe

Industry updates

Staining solution  for cataract surgeries available as vial and syringe
Colin Kerr
Colin Kerr
Published: Sunday, January 1, 2017
[caption id="attachment_6216" align="alignnone" width="750"]Vioron staining solution Vioron staining solution[/caption] STAINING SOLUTION Vioron is Geuder’s number one tissue staining solution for cataract surgeries, and is available as vial and syringe.“It consists of trypan blue and ensures an effective staining and thus brilliant visualisation of the anterior lens capsule,” said a company spokesman. “This staining solution enables an excellent distinction of the capsulorhexis margin. It is quick and easy to apply, and applicable to a variety of further indications, e.g. congenital or (hyper) mature cataract surgery,” added the spokesman. www.geuder.com EXPANDED CUSTOMER REACH HOYA has announced a definitive agreement to acquire Performance Optics, including its subsidiaries VISION EASE and Daemyung Optical. Performance Optics is a global ophthalmic lens manufacturer specialising in polycarbonate, photochromic, polarised and high-index eyeglass lenses. “The acquisition of Performance Optics expands HOYA’s customer reach, particularly through VISION EASE’s presence in the Americas and its strengths in polycarbonate products and technologies,” said Girts Cimermans, CEO of HOYA Vision Care. “Performance Optics provides HOYA with additional capabilities,” he added. www.hoya.com NEW APPOINTMENT Carl Zeiss Meditec has appointed Steven C Schallhorn MD as Chief Medical Officer for Global Ophthalmic Devices, consisting of refractive lasers, surgical ophthalmology and ophthalmic diagnostics. Dr Schallhorn will serve on the Executive Leadership Team, providing strategic direction for the business and medical guidance on the clinical use of ZEISS’ portfolio of ophthalmic diagnostic and surgical technologies. The company said Dr Schallhorn will collaborate with key opinion leaders.
Tags: industry, new products, product updates
Latest Articles
From Lab to Life: Corneal Repair Goes Cellular

Long-awaited cellular therapies for corneal endothelial disease enter the clinic.

Read more...

Balancing Innovation and Safety

Ensuring access to advanced cell therapies amid regulatory overhaul.

Read more...

With Eyes on Its Future, ESCRS Celebrates Its Past

Winter Meeting offers opportunities to experiment with new concepts and formats.

Read more...

Best of ESCRS Winter Meeting 2024

Read more...

Following the New Generation

EDOF IOLs an option for eyes with mild comorbidities, showing potential in mini-monovision strategies.

Read more...

Refocus on Multifocals

Trifocal IOLs continue to improve as consensus grows regarding indications and contraindications.

Read more...

Common Myths in Presbyopia Correction

Patient education key to satisfaction with refractive IOLs.

Read more...

Reversible Multifocality

Two-lens combination offers low-risk spectacle independence for cataract patients and presbyopes.

Read more...

Managing a Cataract Surgery Refractive Miss

Weighing the pros and cons of options for intraocular intervention.

Read more...

Unleashing OCT’s Full Potential

Performance of newest tool for corneal evaluation meets or beats older standard technologies.

Read more...

;